Citations

Showing 10 of 108119 citations.

Effect of Comedications and Endotoxins on Mesenchymal Stem Cell Secretomes, Migratory and Immunomodulatory Capacity
Durand, Nisha , Russell, Athena , Zubair, Abba C. , Zubair, Abba C

Mayo Clinic

Journal of Clinical Medicine | April 12, 2019 | Volume: 8 | Issue: 4 | Pages: 497

10.3390/jcm8040497 | PMID 30979082 Get It

Mesenchymal stem cells (MSCs) are becoming an increasingly popular therapeutic option among patients with a broad range of ailments to modulate immunity and induce regeneration. The majority of patients receiving these MSC therapies are on concurrent medication or have ongoing infection. In the present study, we examined the effect of immunosuppressive drugs and lipopolysaccharides (LPS)/endotoxins on the secretory profile, migration towards site of injury, and suppression of lymphocyte proliferation of bone marrow-derived MSCs (BMSCs). Generally, LPS coculture augmented the secretory capacity of BMSCs while exposure to immunosuppressive drugs resulted primarily in no change or attenuated secretion, with some cases of increased secretion, dependent on the cytokine assayed. Among the immunosuppressants evaluated, Hydrocortisone had the most widespread inhibitory effect, while LPS from E. coli O111:B4 had the most potent stimulatory effect. In addition, we also showed that Hydrocortisone or LPS from E. coli O111:B4 affected the migratory and immunosuppressive capacity of BMSCs. Following simulation with Hydrocortisone, BMSC migration was attenuated, and immunosuppressive capacity against T cell proliferation was enhanced, however, the opposite effects were seen with LPS from E. coli O111:B4. Our data suggests that the clinical outcomes of MSC-based therapy are affected by the use of immunosuppressive medication or the presence of endotoxemia in patients.
Single Antibody Detection of T‐Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T‐Cell Neoplasms and Monotypic Small CD8‐Positive Subsets of Uncertain Significance
Jevremović, Dragan , Otteson, Gregory E., Timm, Michael, Olteanu, Horatiu , Timm, Michael M, Olteanu, Horatiu , Horna, Pedro , Jevremovic, Dragan , Shi, Min

Mayo Clinic

Cytometry Part B: Clinical Cytometry | April 12, 2019 | Volume: 98 | Issue: 1 | Pages: 99-107

10.1002/cyto.b.21782 | PMID 30972977 Get It

BackgroundThe diagnosis of T‐cell neoplasms is often challenging, due to overlapping features with reactive T‐cells and limitations of currently available T‐cell clonality assays. The description of an antibody specific for one of two mutually exclusive T‐cell receptor (TCR) β‐chain constant regions (TRBC1) provide an opportunity to facilitate the detection of clonal TCRαβ T‐cells based on TRBC‐restriction.MethodsTwenty patients with mature T‐cell neoplasms and 44 patients without evidence of T‐cell neoplasia were studied. Peripheral blood (51), bone marrow (10), and lymph node (3) specimens were evaluated by 9‐color flow cytometry including TRBC1 (CD2/CD3/CD4/CD5/CD7/CD8/CD45/TCRγδ/TRBC1 and/or CD2/CD3/CD4/CD5/CD7/CD8/CD26/CD45/TRBC1). Monophasic TRBC1 expression on any immunophenotypically distinct CD4‐positive or CD8‐positive/TCRγδ‐negative T‐cell subset was considered indicative of clonality.ResultsMonophasic (clonal) TRBC1 expression was identified on immunophenotypically abnormal T‐cells from all 20 patients with T‐cell malignancies (100% sensitivity), including 17 cases with either >97% or <3% TRBC1‐positive events, and three cases with monophasic homogenous TRBC1‐dim expression. All immunophenotypically distinct CD4‐positive and CD8‐positive/TCRγδ‐negative T‐cell subsets from 44 patients without T‐cell malignancies showed the expected mixture of TRBC1‐positive and TRBC‐1‐negative subpopulations (non‐clonal), except for seven patients (16%) with very small CD8‐positive T‐cell subsets exhibiting a monophasic (clonal) pattern.ConclusionInclusion of a single anti‐TRBC1 antibody into a diagnostic T‐cell flow cytometry panel facilitates the rapid identification of T‐cell neoplasms, in addition to small monotypic CD8‐positive subsets of uncertain significance. © 2019 International Clinical Cytometry Society
Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis
Crowson, Cynthia S. , Hein, Molly S., Pendegraft, Richard S., Strausbauch, Michael, Niewold, Timothy B. , Ernste, Floranne C. , Dvergsten, Jeffrey , Amin, Shreyasee , Muskardin, Theresa Wampler , Baechler, Emily C., Reed, Ann M. , Strausbauch, Michael A, Reed, Ann M , Peterson, Erik J

Mayo Clinic

ACR Open Rheumatology | April 11, 2019 | Volume: 1 | Issue: 2 | Pages: 83-89

10.1002/acr2.1011 | PMID 31777784 Get It

ObjectiveOur aim was to identify cytokines and chemokines in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) that predict changes in disease activity.MethodsMultiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of interferon (IFN)‐regulated chemokines and other pro‐ and anti‐inflammatory cytokines specific to differentiation of specific T‐cell and innate pathways. Cytokine scores were computed for IFNCK (IP‐10, MCP‐1), Th1 (IFNɣ, TNFα, and IL2), Th2 (IL4, IL10, IL12, and IL 13), Th17 (IL6, IL17, IL1β), macrophage (MIP‐1α, MIP‐1β, IL8), and regulatory (IL10, TNFα) factors. Spearman correlation and mixed models were used to examine whether cytokines at a previous visit predict change in disease activity at the next visit.ResultsThe study included 36 patients (16 DM and 20 JDM) with at least two visits (87 patient intervals between two visits). Mean age (SD) at inclusion was 56.9 (18.4) years for DM and 10.8 (6.6) years in JDM, 67% of patients were female, 89% Caucasian. The mean (SD) physician global, muscle and extra‐muscular disease activity Visual Analog Scale scores at inclusion were 41 (26), 36 (30), and 34 (21) mm, respectively. The change in IFN score from one visit to the next was associated with the change in physician global (P = 0.010) and extramuscular (P < 0.001) disease activity scores. Preliminary results revealed significant correlations of previous IFNCK score and IL‐6 with subsequent disease activity measures, but after adjustment for multiple visits per patient, these associations did not reach statistical significance.ConclusionThere is a potential relationship between IFNCK and other cytokine scores seen in adult and juvenile DM with future disease states.
Comment on “Chronic Migraine – Evolution of the Concept and Clinical Implications”
Boes, Christopher J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 11, 2019 | Volume: 59 | Issue: 4 | Pages: 623-623

10.1111/head.13518 | PMID 30973203 Get It

Clinical implementation of respiratory‐gated spot‐scanning proton therapy: An efficiency analysis of active motion management
Gelover, Edgar, Deisher, A., Herman, Michael , Johnson, J. , Kruse, Jon J. , Tryggestad, E., Deisher, Amanda J, Herman, Michael G., Johnson, Jedediah E, Tryggestad, Erik J

Mayo Clinic

Journal of Applied Clinical Medical Physics | April 11, 2019 | Volume: 20 | Issue: 5 | Pages: 99-108

10.1002/acm2.12584 | PMID 30972922 Get It

AbstractPurposeThe aim of this work is to describe the clinical implementation of respiratory‐gated spot‐scanning proton therapy (SSPT) for the treatment of thoracic and abdominal moving targets. The experience of our institution is summarized, from initial acceptance and commissioning tests to the development of standard clinical operating procedures for simulation, motion assessment, motion mitigation, treatment planning, and gated SSPT treatment delivery.Materials and methodsA custom respiratory gating interface incorporating the Real‐Time Position Management System (RPM, Varian Medical Systems, Inc., Palo Alto, CA, USA) was developed in‐house for our synchrotron‐based delivery system. To assess gating performance, a motion phantom and radiochromic films were used to compare gated vs nongated delivery. Site‐specific treatment planning protocols and conservative motion cutoffs were developed, allowing for free‐breathing (FB), breath‐holding (BH), or phase‐gating (Ph‐G). Room usage efficiency of BH and Ph‐G treatments was retrospectively evaluated using beam delivery data retrieved from our record and verify system and DICOM files from patient‐specific quality assurance (QA) procedures.ResultsMore than 70 patients were treated using active motion management between the launch of our motion mitigation program in October 2015 and the end date of data collection of this study in January 2018. During acceptance procedures, we found that overall system latency is clinically‐suitable for Ph‐G. Regarding room usage efficiency, the average number of energy layers delivered per minute was <10 for Ph‐G, 10‐15 for BH and ≥15 for FB, making Ph‐G the slowest treatment modality. When comparing to continuous delivery measured during pretreatment QA procedures, the median values of BH treatment time were extended from 6.6 to 9.3 min (+48%). Ph‐G treatments were extended from 7.3 to 13.0 min (+82%).ConclusionsActive motion management has been crucial to the overall success of our SSPT program. Nevertheless, our conservative approach has come with an efficiency cost that is more noticeable in Ph‐G treatments and should be considered in decision‐making.
Living Donor Liver Transplantation: Overview, Imaging Technique, and Diagnostic Considerations
Hecht, Elizabeth M. , Kambadakone, Avinash , Wang, Zhen J. , Fidler, Jeff L. , Griesemer, Adam , Fowler, Kathryn J. , Heimbach, Julie K. , Fidler, Jeff L.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 54-64

10.2214/ajr.18.21034 | PMID 30973783 Get It

Multimodality Imaging of Ileal Neuroendocrine (Carcinoid) Tumor
Gupta, Akshya , Lubner, Meghan G. , Menias, Christine O. , Mellnick, Vincent M. , Elsayes, Khaled M. , Pickhardt, Perry J. , Mellnick, Vincent

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 45-53

10.2214/ajr.18.21025 | PMID 30973780 Get It

Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)
Dao, Dyda , Jatoi, Aminah , Hurria, Arti , Muss, Hyman B. , Cohen, Harvey Jay, Citron, Marc L., Budman, Daniel R., Sedrak, Mina S. , Lafky, Jacqueline M., McMurray, Ryan, Le-Rademacher, Jennifer G , Zemla, Tyler , Freedman, Rachel A. , Shulman, Lawrence N. , McMurray, Ryan P. , Partridge, Ann H. , Carey, Lisa A. , Sedrak, Mina S. , Le‐Rademacher, Jennifer

Mayo Clinic

The Oncologist | April 11, 2019 | Volume: 24 | Issue: 6 | Pages: e284-e291

10.1634/theoncologist.2018-0803 | PMID 30975921 Get It

Abstract Background Less than 3% of older patients with cancer are enrolled in clinical trials. To reverse this underrepresentation, we compared older patients enrolled with older-patient-specific trials, defined as those designed for older patients with cancer, with those enrolled in age-unspecified trials. Materials and Methods We focused on individual patient data from those ≥65 years (younger patients excluded) and included all Alliance phase III adjuvant breast cancer trials from 1985–2012. Results Among 2,277 patients, 1,014 had been enrolled to older-patient-specific and 1,263 to age-unspecified trials. The median age (range) in the older-patient-specific trials was 72 (65–89) years compared with 68 (65–84) years in the cohort of older patients in age-unspecified trials; p &lt; .0001. A greater percentage of patients 75 years or older had enrolled in older-patient-specific trials compared with the cohort of age-unspecified trials: 26% versus 6% (p &lt; .0001). Median overall survival (OS) was 12.8 years (95% confidence interval [CI], 11.9–13.7) and 13.5 years (95% CI, 12.9–14.1) for older-patient-specific and age-unspecified trials, respectively. OS was comparable (hazard ratio [HR], 1.08; 95% CI, 0.92–1.28; p = .34; referent: age-unspecified trials), after adjusting for age, estrogen receptor status, tumor size, and lymph node status. Similar findings were reached for recurrence-free survival. A lower rate of grade 3–5 adverse events (hematologic and nonhematologic) was reported in older-patient-specific trials (43% vs. 58%; p &lt; .0001). Sensitivity analysis with chemotherapy only trials and subset analysis, adjusted for performance score, yielded similar OS results. Conclusion Older-patient-specific trials appear to address this underrepresentation of older patients with ostensibly comparable outcomes. Clinical trial identification numbers. NCT00003088 (CALGB 9741); NCT00024102 (CALGB 49907); NCT00068601 (CALGB 40401); NCT00005970 (NCCTG N9831)
Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis
Aljama, Mohammed A. , Lacy, Martha Q. , Dingli, David , Muchtar, Eli , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Warsame, Rahma , Kourelis, Taxiarchis , Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Go, Ronald S , Muchtar, E , Dingli, David , Sidiqi, M Hasib , Dispenzieri, Angela , Gertz, Morie A. , Buadi, Francis K. , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | April 11, 2019 | Volume: 3 | Issue: 8 | Pages: 1226-1229

10.1182/bloodadvances.2019032458 | PMID 30975646 Get It

Abstract We retrospectively reviewed the utility of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and transthoracic echocardiogram (TTE) in diagnosing cardiac involvement in patients with biopsy-proven systemic immunoglobulin light chain amyloidosis seen at the Mayo Clinic between 1 January 2006 and 30 December 2015. We analyzed 2 cohorts: patients undergoing endomyocardial biopsy for suspicion of cardiac involvement (cohort 1) and patients who had serum NT-proBNP and comprehensive echocardiographic evaluation at diagnosis (cohort 2). Of 179 patients undergoing endomyocardial biopsy (cohort 1), 173 (97%) had evidence of amyloid deposition, with 159 having NT-proBNP performed at the time of the procedure. The NT-proBNP was elevated (&gt;300 pg/mL) in all 159 patients (sensitivity, 100%; median NT-proBNP, 4917 pg/mL; range, 355-69 541). The left ventricular ejection fraction, interventricular septal thickness, and strain rate were abnormal in 89/168 (53%), 102/64 (61%) and 92/95 (97%), respectively. Among cohort 2 (n = 342), 259 (76%) had an elevated NT-proBNP, of whom 237 (92%) had an abnormality detected on TTE. Of 83 patients with normal NT-proBNP &lt;300 pg/mL, 27 (33%) had an abnormality on TTE (all with borderline strain rate −18% to −15%). Only 5/27 patients were considered to have possible early cardiac involvement and none had any other diagnostic or classical features of amyloidosis on TTE. The combination of NT-proBNP and comprehensive echocardiographic evaluation can diagnose cardiac amyloidosis negating the need for endomyocardial biopsy. A negative NT-proBNP rules out clinically meaningful cardiac involvement and may obviate the routine use of TTE in patients with a low clinical suspicion of cardiac amyloidosis.
Bleeding Liver Masses: Imaging Features With Pathologic Correlation and Impact on Management
Menias, Christine O. , Pickhardt, Perry J. , Gaballah, Ayman H. , Yedururi, Sireesha , Elsayes, Khaled M. , Thomas, Aaron J., Shaaban, Akram M.

Mayo Clinic

American Journal of Roentgenology | April 11, 2019 | Volume: 213 | Issue: 1 | Pages: 8-16

10.2214/ajr.19.21240 | PMID 30973778 Get It